Description
Product Usage Information
CDDO-Me is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 0.99 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
CDDO-Me (bardoxolone methyl) is a synthetic triterpenoid that induces apoptosis and differentiation in cancer cells, and exhibits strong antiproliferative and antiangiogenic activities (1). CDDO-Me activates nuclear factor-like 2 (NRF2) transcriptional activator, which regulates oxidative stress response gene expression through binding of antioxidant response element (ARE) promoter gene regions. CDDO-Me interacts with the NRF2 inhibitor INrf2 (also called KEAP1), resulting in the release of NRF2 from the proteasome pathway and translocation of NRF2 into the nucleus (2). Additionally, CDDO-Me binds IKKβ to block the targeting of NF-κB p65 to the nucleus and inhibits NF-κB activation and downstream pro-inflammatory signaling pathways (3). CDDO-Me has been studied as an anticancer and anti-inflammatory drug, with potential to treat patients with chronic kidney disease associated with diabetes (4). Low doses of CDDO-Me may exert therapeutic effects on cardiac function in models of chronic heart failure (5).
Alternate Names
12-dioxooleana-1,9(11)-dien-28-oic acid methyl ester; 2-Cyano-3; CDDO Methyl ester; NSC 713200; RTA 402
